[HTML][HTML] Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first-or second-generation tyrosine kinase inhibitors
CT Huang, CA Lin, TJ Su, CY Yang, TH Tsai, CL Hsu… - BMC cancer, 2023 - Springer
Abstract Background The T790M mutation is the major resistance mechanism to first-and
second-generation TKIs in EGFR-mutant NSCLC. This study aimed to investigate the utility …
second-generation TKIs in EGFR-mutant NSCLC. This study aimed to investigate the utility …
Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first-or second-generation tyrosine kinase inhibitors
H Chun-Ta, L Chih-An, S Te-Jen, Y Ching-Yao… - BMC …, 2023 - search.proquest.com
Background The T790M mutation is the major resistance mechanism to first-and second-
generation TKIs in EGFR-mutant NSCLC. This study aimed to investigate the utility of droplet …
generation TKIs in EGFR-mutant NSCLC. This study aimed to investigate the utility of droplet …
Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first-or second-generation tyrosine kinase inhibitors.
CT Huang, CA Lin, TJ Su, CY Yang, TH Tsai… - BMC …, 2023 - search.ebscohost.com
Abstract Background: The T790M mutation is the major resistance mechanism to first-and
second-generation TKIs in EGFR-mutant NSCLC. This study aimed to investigate the utility …
second-generation TKIs in EGFR-mutant NSCLC. This study aimed to investigate the utility …
[HTML][HTML] Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first-or second-generation tyrosine kinase inhibitors
CT Huang, CA Lin, TJ Su, CY Yang… - BMC …, 2023 - bmccancer.biomedcentral.com
The T790M mutation is the major resistance mechanism to first-and second-generation TKIs
in EGFR-mutant NSCLC. This study aimed to investigate the utility of droplet digital PCR …
in EGFR-mutant NSCLC. This study aimed to investigate the utility of droplet digital PCR …
[HTML][HTML] Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first-or second-generation tyrosine kinase inhibitors
CT Huang, CA Lin, TJ Su, CY Yang, TH Tsai… - BMC Cancer, 2023 - ncbi.nlm.nih.gov
Background The T790M mutation is the major resistance mechanism to first-and second-
generation TKIs in EGFR-mutant NSCLC. This study aimed to investigate the utility of droplet …
generation TKIs in EGFR-mutant NSCLC. This study aimed to investigate the utility of droplet …
Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first-or second-generation tyrosine kinase inhibitors
CT Huang, CA Lin, TJ Su, CY Yang, TH Tsai… - BMC …, 2023 - pubmed.ncbi.nlm.nih.gov
Background The T790M mutation is the major resistance mechanism to first-and second-
generation TKIs in EGFR-mutant NSCLC. This study aimed to investigate the utility of droplet …
generation TKIs in EGFR-mutant NSCLC. This study aimed to investigate the utility of droplet …
Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first-or second-generation tyrosine kinase inhibitors
C Huang, C Lin, T Su, C Yang, T Tsai, C Hsu, W Liao… - BMC Cancer, 2023 - europepmc.org
Background The T790M mutation is the major resistance mechanism to first-and second-
generation TKIs in EGFR-mutant NSCLC. This study aimed to investigate the utility of droplet …
generation TKIs in EGFR-mutant NSCLC. This study aimed to investigate the utility of droplet …
[PDF][PDF] Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first-or second-generation tyrosine kinase inhibitors
CT Huang, CA Lin, TJ Su, CY Yang, TH Tsai… - 2023 - bmccancer.biomedcentral.com
Abstract Background The T790M mutation is the major resistance mechanism to first-and
second-generation TKIs in EGFR-mutant NSCLC. This study aimed to investigate the utility …
second-generation TKIs in EGFR-mutant NSCLC. This study aimed to investigate the utility …